You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Advancing the Care of Heart Failure and Type 2 Diabetes: A Review and Application of the Latest Recommendations

  • Authors: James L. Januzzi Jr, MD, FACC, FESC; Rodica Pop-Busui, MD, PhD
  • CME / ABIM MOC Released: 9/29/2022
  • Valid for credit through: 9/29/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, diabetologists, endocrinologists, primary care physicians, nurses, and all clinicians interested in the care of patients with HF and diabetes.

The goal of this activity is for learners to be better able to enhance recognition and application of the latest guidelines for the use of cardiac biomarkers in the identification and management of HF in patients with T2D.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest recommendations for the management of patients with HF and T2D
    • Utility of cardiac biomarkers for the management of patients with T2D at high cardiovascular risk in accordance with the latest American Diabetes Association (ADA) recommendations
  • Have greater competence related to
    • Improved heart failure recognition and management among patients with concomitant T2D
  • Demonstrate greater confidence in their ability to
    • Apply the latest recommendations to appropriately assess risk of HF in patients with T2D to optimize patient management by an interdisciplinary team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • James L. Januzzi Jr, MD, FACC, FESC

    Hutter Family Professor of Medicine
    Division of Cardiology
    Massachusetts General Hospital
    Faculty
    Baim Institute for Clinical Research
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    James L. Januzzi Jr, MD, FACC, FESC, has the following relevant financial relationships:
    Consultant or advisor for: Abbott Diagnostics; Beckman Coulter; Boehringer Ingelheim; Jana Care; Janssen; Merck; Molecular Templates; Novartis Pharmaceuticals; Prevencio; Quidel; Roche Diagnostics
    Research funding from: Abbott Diagnostics; Applied Therapeutics; Innolife; Novartis Pharmaceuticals
    Monetary compensation for an executive role from: Imbria Pharmaceuticals

  • Rodica Pop-Busui, MD, PhD

    Larry D. Soderquist Professor in Diabetes
    Professor of Internal Medicine, Metabolism, Endocrinology, and Diabetes
    Vice Chair, Clinical Research
    Department of Internal Medicine
    Director, Clinical Research, Mentoring, and Development
    Elizabeth Weiser Caswell Diabetes Institute
    Co-Director, JDRF Center of Excellence
    University of Michigan
    President-Elect, Medicine and Science, American Diabetes Association
    Ann Arbor, Michigan

    Disclosures

    Rodica Pop-Busui, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Averitas Pharma; Boehringer Ingelheim; Nevro Corporation; Novo Nordisk; Reata Pharmaceutical; Regenacy; Roche
    Research funding from: Medtronic; Novo Nordisk

Editor

  • Joy P. Marko, MS, APN-C, CCMEP

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Advancing the Care of Heart Failure and Type 2 Diabetes: A Review and Application of the Latest Recommendations

Authors: James L. Januzzi Jr, MD, FACC, FESC; Rodica Pop-Busui, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 9/29/2022

Valid for credit through: 9/29/2023

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print